Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Milpied

Showing results (171-180 of 240) with videos related to

Pageof 24
Sort By:
Genes, Chromosomes & Cancer|September 17, 1998
Detection of t(11;14) using interphase molecular cytogenetics in mantle cell lymphoma and atypical chronic lymphocytic leukemiaH Avet-Loiseau, R Garand, F Gaillard, et al.
Bone Marrow Transplantation|January 7, 1998
Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia in first remission: long-term results for 42 patients conditioned with an intensified regimen (TBI, high-dose Ara-C and melphalan)E Deconinck, J Y Cahn, N Milpied, et al.
Leukemia|February 1, 2012
Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMTA Spyridonidis, M Labopin, C Schmid, et al.
Bone Marrow Transplantation|July 12, 2005
Cost effectiveness of day 5 G-CSF (Lenograstim) administration after PBSC transplantation: results of a SFGM-TC randomised trialD Valteau-Couanet, C Faucher, A Aupérin, et al.
Bone Marrow Transplantation|July 10, 2012
Incidence and risk factors of EBV reactivation after unrelated cord blood transplantation: a Eurocord and Société Française de Greffe de Moelle-Therapie Cellulaire collaborative studyP Y Dumas, A Ruggeri, M Robin, et al.
Hematology and Cell Therapy|October 1, 1996
[Utilization of herpes simplex virus-1 thymidine kinase gene in stem cell transplantation therapy]P Tiberghien, J Y Cahn, C Ferrand, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2012
A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphomaF Morschhauser, C Recher, N Milpied, et al.
Pathologie-Biologie|September 10, 2013
[How to handle unexpected biological abnormalities observed in the pre-donation workup for hematopoietic stem cell transplantation: an SFGM-TC report on pre-transplant cytomegalovirus, Epstein-Barr virus, Toxoplasma gondii, or syphilis IgM positive serology test]R Duléry, C Giraud, J-L Beaumont, et al.
Leukemia|December 25, 2010
The role of in vivo T-cell depletion on reduced-intensity conditioning allogeneic stem cell transplantation from HLA-identical siblings in patients with follicular lymphomaJ Delgado, C Canals, M Attal, et al.
Leukemia|October 23, 2009
Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicinP Chevallier, T Prebet, A Pigneux, et al.
Pageof 24

Showing results (171-180 of 240) with videos related to

Sort By:
Pageof 24
Genes, Chromosomes & Cancer|September 17, 1998
Detection of t(11;14) using interphase molecular cytogenetics in mantle cell lymphoma and atypical chronic lymphocytic leukemiaH Avet-Loiseau, R Garand, F Gaillard, et al.
Bone Marrow Transplantation|January 7, 1998
Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia in first remission: long-term results for 42 patients conditioned with an intensified regimen (TBI, high-dose Ara-C and melphalan)E Deconinck, J Y Cahn, N Milpied, et al.
Leukemia|February 1, 2012
Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMTA Spyridonidis, M Labopin, C Schmid, et al.
Bone Marrow Transplantation|July 12, 2005
Cost effectiveness of day 5 G-CSF (Lenograstim) administration after PBSC transplantation: results of a SFGM-TC randomised trialD Valteau-Couanet, C Faucher, A Aupérin, et al.
Bone Marrow Transplantation|July 10, 2012
Incidence and risk factors of EBV reactivation after unrelated cord blood transplantation: a Eurocord and Société Française de Greffe de Moelle-Therapie Cellulaire collaborative studyP Y Dumas, A Ruggeri, M Robin, et al.
Hematology and Cell Therapy|October 1, 1996
[Utilization of herpes simplex virus-1 thymidine kinase gene in stem cell transplantation therapy]P Tiberghien, J Y Cahn, C Ferrand, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2012
A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphomaF Morschhauser, C Recher, N Milpied, et al.
Pathologie-Biologie|September 10, 2013
[How to handle unexpected biological abnormalities observed in the pre-donation workup for hematopoietic stem cell transplantation: an SFGM-TC report on pre-transplant cytomegalovirus, Epstein-Barr virus, Toxoplasma gondii, or syphilis IgM positive serology test]R Duléry, C Giraud, J-L Beaumont, et al.
Leukemia|December 25, 2010
The role of in vivo T-cell depletion on reduced-intensity conditioning allogeneic stem cell transplantation from HLA-identical siblings in patients with follicular lymphomaJ Delgado, C Canals, M Attal, et al.
Leukemia|October 23, 2009
Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicinP Chevallier, T Prebet, A Pigneux, et al.
Pageof 24